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Abstract
Background: Chemokines are well known inflammatory factors critical for tumor development in diverse tissues,
including lung cancer. Chemokine (C-C motif) Ligand 2 (CCL2) was one of such chemokines important for both
primary tumor development and metastasis of various cancers. Polymorphism at rs3760396 of CCL2 genes is
associated with the prognosis of non-small cell lung cancer (NSCLC). The goal of our study was to examine the
relationship of genetic polymorphisms rs3760396 with the susceptibility of lung cancer and its pathological
subtypes in Han-ancestry Chinese population.
Methods: rs3760396 G/C polymorphism of CCL2 was genotyped using PCR in 394 patients with lung cancer and
545 cancer-free controls from the same Northeast region of China.
Results: After controlling for gender, age and smoking status, no significant association was observed between
rs3760396 polymorphism and overall lung cancer. However, minor allele G of rs3760396 polymorphism was
significantly associated with increased risk of adenosquamous lung carcinoma with either allelic genetic model
(OR = 5.29, P < 0.001), or dominant genetic model (OR = 9.88, P < 0.001), or genotypic model (GC genotype vs. CC
genotype, OR = 10.73, P < 0.001). Although rs3760396 polymorphism was not significantly associated with
increased risk of adenocarcinoma subtype, it was nominally associated with the pooled outcome of either
adenocarcinoma or adenosquamous carcinoma under allelic genetic model (OR = 1.54, P = 0.023) or dominant
genetic model (OR = 1.57, P = 0.031).
Conclusions: Our study suggested rs3760396 polymorphism of CCL2 is associated not only with prognosis of
NSCLC, but also with risk of lung cancer in a subtype-specific manner. Our results further supported previous
evidence of the important role of CCL2 in lung cancer development.
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Background
Globally, Lung cancer is the most common cancer diag-
nosed and is responsible for one fifth of death due to
cancer [1]. In China, there are 0.7 million incidence
cases, and the mortality caused by lung cancer is up to
0.6 million cases [2]. Most lung cancer patients are diag-
nosed at later stage when the timing for effective surgi-
cal dissection is missed. Its prognosis is relatively poor
with 5-year survival rate at only about 15 % if diagnosed
at later stage. While, the 5-year survival rate can be 30–
40 % if diagnosed at early stage [3]. It has been found
that both genetic and environmental factors are critical
for the development of lung cancer. Although tobacco
smoking can account for up to 80 % of lung cancer
cases, substantial variations exist that cannot be ex-
plained solely by environmental and behavior factors
[4]. Identification of genetic risk factors such as genetic
polymorphism can have important indication for both
early detection and therapy target discovery to improve
the prognosis of lung cancer patients. Recent research
has successfully identified potential genetic variations
associated with the susceptibility of lung Cancer [5–8].
Inflammatory factors including cytokines and chemo-
kines have long been suggested for their role in cancer
development. Chemokines can contribute to tumor cell
proliferation, angiogenesis and metastasis to promote
the advancement of cancer [9]. Dysfunction of CXC
and CC groups of chemokines has been found to in-
volve in the progression of lung cancer [10, 11]. Che-
mokine (C-C motif ) ligand 2 (CCL2), once named as
monocyte chemotactic protein 1 (MCP-1), belongs to
the CC chemokine family. CCL2 is primarily secreted
by monocytes, macrophages and dendritic cells. It can
recruit inflammatory cells to the sites of inflammation
[12]. Polymorphism rs1024611 in CCL2 gene was re-
ported to be correlated with the metastases of breast
cancer and nasopharyngeal carcinoma [13, 14]. Very
recently, another genetic polymorphism in the pro-
moter region of CCL2 gene, rs3760396, has been re-
ported to be associated with decreased risk of death
for non-small cell lung cancer (NSCLC) in Chinese
population [15]. Our current study sought out to
study whether the same single nucleotide polymorphism
(SNP: rs3760396) of CCL2 is also associated with the
occurrence of lung Cancer and its pathological subtypes
in a Chinese population.
Methods
Ethics, consent and permissions
The study was approved by the Ethical Committee of
Capital Medical University Electric Power Teaching
Hospital (Beijing, China). Consents to participate in
the study from the participants (or legal guardian) were
obtained.
Consent to publish
We had obtained the consents to publish from the par-
ticipant (or legal parent or guardian for children) to re-
port individual patients’ data in any form (including
images, videos, voice recordings etc.).
Study subjects
Lung cancer patients were recruited from Capital
Medical University Electric Power Teaching Hospital
(Beijing, China) between Sep. 2011 to Sep. 2012. They
were all newly diagnosed cases with histopathological
confirmation. Lung cancer cases were classified histo-
logically as squamous carcinomas, adenocarcinomas,
adenosquamous carcinoma, small cell carcinomas, and
large cell carcinomas. Patients would have been ex-
cluded if they had previous history of cancers, or his-
tory of chemotherapy/radiotherapy for other cancers.
All control subjects are free of history of cancer or
chemotherapy/radiotherapy.
DNA extraction and genotyping assays
Peripheral blood samples were collected with EDTA
tube and stored at −70 °C. DNA was purified from
whole blood using the RelaxGene Blood DNA System
(TianGen Biotech Co Ltd., Beijing, China) according to
the manufacturer’s protocol. SNP rs3760396 located in
gene chemokine (C-C motif ) ligand 2 (CCL2) was geno-
typed using a Taqman SNP Genotyping Assay (Applied
Biosystems, Foster City, CA, USA) with ABI 7900 HT
Fast Real Time PCR System (Applied Biosystems). Its
assay ID is C_27478341_10. Assays were performed with
Taqman Universal Master Mix, Taqman probe, and
10 ng of DNA per reaction. PCR was set up according
to manufacturer’s protocol: 3 min initial denaturation at
95 °C followed by 40 cycles of 95 °C denaturation for
15 s and 60 °C annealing/extension for 1 min. The geno-
typing process was performed blind to group status.
Statistical analysis
Test of Hardy-Weinberg equilibrium of the genotype
distribution was performed using exact tests imple-
mented by Wigginton et al. [16] in PLINK 1.07 software.
Characteristics of case and control groups were examined
with student t-test or chi-squared test using STATA/
SE12.0 (StataCorp LP, TX, USA). Logistic regression ana-
lysis was conducted to assess the association between
the genotypes and overall lung cancer risk in PLINK
1.07 software and STATA/SE12.0 (StataCorp LP, TX,
USA). A p value less than 0.05 was considered to be
nominally significant. A total of 30 models involving up
to six outcome traits and four types of genetic predic-
tors have been tested. Under stringent Bonferroni cor-
rection on 30 tests, P value less than 0.0017 (=0.05/30)
would be considered significant after correction on
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multiple testing. However, keep in mind that many
outcome traits and predictors were related to each
other. So this correction would be over-conservative.
The association of genotypes with the pathohistologi-
cal subtypes and various clinical stages of lung cancer
were examined by multinomial logistic regression.
Three subtypes were evaluated: squamous carcinomas,
adenocarcinomas, adenosquamous carcinoma. Small cell
carcinomas and large cell carcinomas were not included
due to lack of variability of genotypes of rs3760396. Age
and gender and smoking status were included as additive
covariates in above analysis.
Results
In current study, we genotyped CCL2 rs3760396 poly-
morphism in a total of 939 Han-ancestry Chinese sub-
jects, including 395 patients with lung cancer and 545
healthy controls. One sample from case group without
successful genotyping was excluded. Table 1 included
the demographic and characteristics information of all
the subjects. There were less males in cases versus con-
trols (59.4 % vs. 67.3 %) (p = 0.012). Lung cancer patients
were slightly older than controls (mean ± SD: 58.1 ± 9.4
vs 52.3 ± 10.5 years old, p <0.0001). There were signifi-
cantly more smokers in cases (48.0 %) than in healthy
controls (25.7 %) with a p value less than 0.001. There-
fore, in the following SNP association analysis, age, gen-
der and smoking status were included as covariates in
an additive way.
We summarized genotype distribution and allele fre-
quency of rs3760396 SNP in CCL2 gene in controls and
lung cancer cases (Table 2). rs3760396 SNP genotype
distribution in both cases and controls was in agreement
with the Hardy-Weinberg equilibrium (p = 0.40 and 0.53,
respectively). G allele of rs3760396 SNP is the minor al-
lele with higher prevalence in lung cancer patients than
in controls. Its frequencies in controls and lung cancer
patients were 7.5 and 9.8 %, respectively. Genotypes of
rs3760396 SNP have a distribution of 0.7 %/13.6 %/85.7 %
for GG/GC/CC genotypes in controls, and 1.3 %/17.0 %/
81.7 % for GG/GC/CC genotypes in cases, respectively.
We further tested the association of rs3760396 SNP
with the susceptibility of lung cancer (Table 3). Without
including any covariate, there is no significant geno-
typic or allelic association of rs3760396 SNP with lung
cancer (p = 0.24 and p = 0.38, respectively). The associ-
ation is non-significant either under dominant or reces-
sive model (p = 0.10 and p = 0.41, respectively). Since
age, gender and smoking status were significantly asso-
ciated with lung cancer, we further included age, gender
and smoking status as additive covariates in the associ-
ation analysis. Four genetic models were evaluated.
There was no significant association of this SNP with
lung cancer although the point estimate of Odds Ratio
(OR) showed the tendency of correlation between
minor allele G and increased risk of lung cancer: OR =
1.25 and p = 0.2 in allelic model; OR = 1.24 and p = 0.26
in dominant model; OR = 2.07 and p = 0.31 in recessive
model; and p = 0.4 in genotypic model.
Next, we examined the association of rs3760396
SNP with pathological subtypes of lung cancer. Small
cell lung cancer and big cell lung cancer cases are all
homozygous of the major allele C at rs3760396 SNP.
Table 1 Characteristics of Lung Cancer Patients and Controls





Age (year) 58.1 ± 9.4 52.3 ± 10.5 < 0.0001
Han Ethnicities 394 545
Smoking status
Non-smokers 205 405 < 0.001
Smokers 189 140
Histological type
Squamous carcinomas 142 NA
Adenocarcinomas 221 NA
Adenosquamous carcinomas 20 NA
Small cell carcinomas 10 NA









not classified 1 NA
aTwo-sided χ2 test
Table 2 Genotype and Allele Frequencies of the CCL2
rs3760396 polymorphism in lung cancer patients and controls
Controls (%), n = 545 Cases (%), n = 394
Genotypes
GG 4 (0.7 %) 5 (1.3 %)
GC 74 (13.6 %) 67 (17.0 %)
CC 467 (85.7 %) 322 (81.7 %)
Alleles
G 7.5 % 9.8 %
C 92.5 % 90.2 %
CCL2 chemokine (C-C motif) ligand 2 gene
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Therefore, these two subtypes were not included in
the analysis multinomial logistic regression was used.
The results were summarized in Table 4. Because re-
cessive genotypes were present in less than or equal to
four cases in the subtypes of lung cancer, recessive
genetic model was not evaluated. We found that
rs3760396 SNP was significantly associated with ade-
nosquamous carcinoma using either allelic (OR = 5.3
and p < 0.001), dominant (OR = 9.8 and P < 0.001), or
genotypic model (OR = 10.7 and P < 0.001 for GC vs.
CC genotypes) even under conservative Bonferroni
correction (p value cutoff 0.0017). There is no signifi-
cant association between rs3760396 and either adeno-
carcinoma or squamous cell carcinoma.
We noticed that, the point estimates of OR for the
association between the minor allele G of rs3760396
and adenocarcinoma is in the same direction as that in
adenosquamous carcinoma, whereas the point estimate
of OR was in opposite direction for squamous cell car-
cinoma. We speculated that rs3760396 polymorphism
may be more associated with the adenocarcinoma cell
components, which is shared between adenocarcinoma
and adenosquamous carcinoma, than the squamous
cell components in adenosquamous carcinoma. To test
this hypothesis, we pooled the two pathological subtype
of lung cancer together and examined the genetic asso-
ciation with Multinomial Logistic Regression. Again,
age, geneder and smoking status were included as additive
covariates. The results were presented in Table 5. Interest-
ingly, nominally significant association remained between
rs3760396 and the pooled pathological subtypes in which
adenocarcinoma cell components were common (Relative
Risk Ratio RRR = 1.54 and P = 0.02 in allelic model, and
RRR = 1.57 and p = 0.03 in dominant model). Note that
this association could not pass stringent Bonferroni cor-
rected p value cut off (p < 0.0017).
We assessed whether the differential association of
rs3760396 with pathological subtypes of lung cancers is
mediated through differential distribution of clinical
stages. Our analysis showed that adenosquamous cell
carcinoma, adenocarcinoma and squamous cell carcin-
oma did exhibit differential distribution of clinical stages
Table 3 Statistical tests on the association of CCL2 rs3760396 polymorphism with lung cancer
Model Comparison Covariates OR P-value
Allelic G vs C none 1.35 0.38
Genotypic GC vs GG vs CC none NA 0.24
Dominant GG/GC vs CC none 1.34 0.10
Recessive GG vs GC/CC none 1.74 0.41
Allelic G vs C Age, gender, smoking status 1.25 0.20
Genotypic GC vs GG vs CC Age, gender, smoking status NA 0.40
Dominant GG/GC vs CC Age, gender, smoking status 1.24 0.26
Recessive GG vs GC/CC Age, gender, smoking status 2.07 0.31
CCL2 chemokine (C-C motif) ligand 2 gene, OR odds ratio
Table 4 Association of CCL2 rs3760396 polymorphism with pathological subtypes of lung cancer
Genetic model Comparison RRRa vs. controls p-value 95 % CI_Lower 95 % CI_Upper
Adenosquamous carcinoma
allelic G vs C 5.29 < 0.001* 2.40 11.66
Dominant GC/GG vs CC 9.88 < 0.001* 3.61 27.00
genotypic GC vs CC 10.73 < 0.001* 3.88 29.71
Adenocarcinoma
allelic G vs C 1.33 0.16 0.90 1.98
Dominant GC/GG vs CC 1.29 0.25 0.84 1.99
genotypic GC vs CC 1.22 0.39 0.78 1.90
GG vs CC 2.89 0.16 0.66 12.62
Squamous cell carcinoma
allelic G vs C 0.82 0.48 0.47 1.43
Dominant GC/GG vs CC 0.79 0.43 0.43 1.43
genotypic GC vs CC 0.76 0.39 0.41 1.41
GG vs CC 1.26 0.84 0.13 12.51
aRRR relative risk ratio; *p < 0.05. CCL2 chemokine (C-C motif) ligand 2 gene, CI confidence interval
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(chi-squared test p < 0.001). Therefore, we further in-
cluded clinical stages as covariate. After controlling for
clinical stages, SNP rs3760396 is still differentially asso-
ciated with pathological subtypes using squamous cell
carcinoma as reference (Table 6). In fact, we directly
evaluated whether SNP rs3760396 is associated with the
stages of lung cancer. Two analysis strategies were used:
with control as reference outcome, there is no significant
association of this SNP with any of the 4 stages of lung
cancer (Results not shown); with case only analysis using
stage 1 as reference outcome, there is no significant as-
sociation of this SNP with stages of lung cancer either
(Table 7). This provides another line of reasoning that
our observed association of SNP rs3760396 with sub-
types of lung cancer is not mediated through relation-
ship with clinical stages.
Discussion
Our current study found that the minor allele G of genetic
polymorphism in CCL2 gene, rs3760396, was significantly
associated with increased risk of adenosquamous lung car-
cinoma, after controlling for age, gender, and smoking sta-
tus. The association remained nominally significant when
adenosquamous lung carcinoma and adenocarcinoma were
pooled together as a merged outcome phenotype, although
the association p value could not pass over-conservative
Bonferroni correction. This association was not observed
for squamous cell lung carcinoma. There was no significant
association of this SNP with overall lung cancer susceptibil-
ity, indicating subtype-specific effect of this SNP.
Furthermore, this subtype specific association is not
confounded by the differential distribution of clinical
stages among subtypes of lung cancer. In fact, there was
no significant association between this SNP and clinical
stages of lung cancer.
Our results pointed to a lung cancer subtype specific
molecular mechanism link between CCL2 and adenos-
quamous carcinoma. To our best knowledge, our study
represented the first such report. Our study further in-
dicated the potential link of CCL2 rs3760396 with the
adenocarcinoma cell components shared between ade-
nosquamous carcinoma and adenocarcinoma. Our re-
sults extended recent finding in Chinese population
that the same SNP is associated with the outcome of
NSCLC [15]. Thus, the same genetic variation of CCL2
gene can affect both the risk of occurrence of adenos-
quamous cell lung carcinoma and the outcome of non-
small cell lung cancer.
Interestingly, the association of CCL2 with adenocar-
cinoma or adenosquamous carcinoma in other tissue
Table 5 Association of CCL2 rs3760396 polymorphism with lung cancer cases classified as either adenocarcinoma or
adenosquamous carcinoma
Genetic model Comparison RRR (vs Con) p-value 95 % CI_Lower 95 % CI_Upper
adenocarcinoma/adenosquamous carcinoma
allelic G vs C 1.54 0.023 1.06 2.24
dominant GC/GG vs CC 1.57 0.031 1.04 2.36
genotypic GC vs CC 1.51 0.055 0.99 2.30
GG vs CC 2.75 0.183 0.62 12.06
recessive GG vs CC/GC 2.55 0.215 0.58 11.22
CCL2 chemokine (C-C motif) ligand 2 gene, RRR relative risk ratio, CI confidence interval
Table 6 association of CCL2 rs3760396 polymorphism with pathological subtypes of lung cancer
Genetic model Comparison RRR p-value 95 % CI_Lower 95 % CI_Upper
Squamous cell carcinoma Reference
Outcome
Adenosquamous carcinoma
allelic G vs C 6.77 < 0.001* 2.58 17.74
Dominant GC/GG vs CC 12.91 < 0.001* 4.10 40.61
genotypic GC vs CC 14.42 < 0.001* 4.48 46.41
GG vs CC
Adenocarcinoma
allelic G vs C 1.73 0.09 0.93 3.24
Dominant GC/GG vs CC 1.76 0.10 0.89 3.47
genotypic GC vs CC 1.68 0.15 0.83 3.40
Note: Inclusion of clinical stages as a covariate in case only analysis on the association of CCL2 rs3760396 polymorphism with pathological subtypes of lung
cancer. Squamous cell carcinoma was used as a reference subtype. CCL2 chemokine (C-C motif) ligand 2 gene, RRR relative risk ratio, CI confidence interval
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types has been reported. For example, recent study
found increased expression of CCL2 mRNA in human
gallbladder adenocarcinoma than those in human
chronic cholecystitis [17]; Exogenous CCL2 expression
by murine colon adenocarcinoma cells have been found
to promote its lung metastases through promoting neo-
vascularization [18, 19]. A pilot study [20] reported that
CCL2 -2518A/G polymorphism is associated with gen-
etic susceptibility to NSCLC in Han nationality of
North China. rs3760396 has been rarely studied in lung
cancer other than association between rs3760396 and
decreased risk of death for non-small cell lung cancer
[15]. A pilot case–control study in Chinese population
[21] reported that the frequency of the heterozygote C/G
at promoter of CCL2 was significantly less in ovarian can-
cer than in healthy controls.
The association between genetic polymorphism in
CCL2 and lung cancer is biologically plausible. CCL2
plays an important role in the tumor microenviron-
ment. CCL2 was reported as a transforming growth
factor-β (TGF-β) target gene in endothelial cells (ECs).
CCL2 mediates TGF-β–stimulated angiogenesis by en-
hancing migration of mural cells toward ECs and thus
promoting the maturation of new blood vessels [22].
rs3760396 is located in the promoter region of CCL2
gene. It has been found that this SNP is associated with
transcription factor binding sites and can modify tran-
scriptional activity, and thus to be a functional SNP
[23]. Previous studies revealed that CCL2 could regu-
late angiogenesis process in cancer development and
metastasis through its critical role in macrophage re-
cruitment [18]. Our current study together with other
studies of rs3760396 [21] in Chinese population suggest
that the G allele of rs3760396 in the promoter of CCL2
plays an important role in the function of CCL2. The
exact mechanism underlying the link of rs3760396 of
CCL2 with adenosquamous carcinoma would need fur-
ther investigation.
Due to the limited sample size for small cell lung
cancer and big cell lung cancer subtypes, we only eval-
uated the subtype specific effect of t rs3760396 in ade-
nosquamous lung carcinoma, adenocarcinoma, and
squamous cell carcinoma. It would warrant further in-
vestigation whether this SNP is also associated with
increased risk of other pathological subtypes of lung
cancer besides adenosquamous lung carcinoma. Fu-
ture replication study is needed to confirm our finding
and generalize our findings in other populations. Fu-
ture functional study would be necessary to identify
molecular mechanisms underlying the association.
Conclusion
The minor allele of SNP rs3760396 of CCL2 gene is as-
sociated with increased risk of adenosquamous lung
carcinoma, but not overall lung cancer in Chinese Han
ethnicity population. The underlying functional mech-
anism would worth further investigation.
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Table 7 Analysis on association of SNP rs3760396 with clinical stages of lung cancer within cases
Clinical stages Genetic model Comparison RRR p-value 95 % CI_Lower 95 % CI_Upper
1 Reference Stage
2 allelic G vs C 0.76 0.50 0.35 1.68
genotypic GC vs CC 0.55 0.19 0.23 1.35
Dominant GC/GG vs CC 0.63 0.30 0.26 1.51
3 allelic G vs C 0.68 0.33 0.31 1.49
genotypic GC vs CC 0.52 0.15 0.22 1.27
Dominant GC/GG vs CC 0.57 0.21 0.24 1.37
4 allelic G vs C 0.87 0.76 0.35 2.12
genotypic GC vs CC 0.81 0.67 0.30 2.14
Dominant GC/GG vs CC 0.82 0.70 0.31 2.18
SNP single nucleotide polymorphism, RRR relative risk ratio, CI confidence interval
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